HK1257233A1 - 預防動脈粥樣硬化及其併發症的藥物及其用途 - Google Patents

預防動脈粥樣硬化及其併發症的藥物及其用途

Info

Publication number
HK1257233A1
HK1257233A1 HK18116269.0A HK18116269A HK1257233A1 HK 1257233 A1 HK1257233 A1 HK 1257233A1 HK 18116269 A HK18116269 A HK 18116269A HK 1257233 A1 HK1257233 A1 HK 1257233A1
Authority
HK
Hong Kong
Prior art keywords
medicine
atherosclerosis
complications
preventing
preventing atherosclerosis
Prior art date
Application number
HK18116269.0A
Other languages
English (en)
Inventor
李季男
Original Assignee
深圳瑞健生命科學研究院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳瑞健生命科學研究院有限公司 filed Critical 深圳瑞健生命科學研究院有限公司
Publication of HK1257233A1 publication Critical patent/HK1257233A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18116269.0A 2016-12-15 2018-12-19 預防動脈粥樣硬化及其併發症的藥物及其用途 HK1257233A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611162237 2016-12-15
CN201611161347 2016-12-15

Publications (1)

Publication Number Publication Date
HK1257233A1 true HK1257233A1 (zh) 2019-10-18

Family

ID=62656680

Family Applications (7)

Application Number Title Priority Date Filing Date
HK18116276.1A HK1257240A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
HK18116273.4A HK1257237A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪肝的藥物及其用途
HK18116275.2A HK1257239A1 (zh) 2016-12-15 2018-12-19 預防和治療肥胖症的藥物及其用途
HK18116272.5A HK1257236A1 (zh) 2016-12-15 2018-12-19 預防和治療高脂血症的藥物及其用途
HK18116270.7A HK1257234A1 (zh) 2016-12-15 2018-12-19 治療冠狀動脈粥樣硬化及其併發症的藥物及其用途
HK18116269.0A HK1257233A1 (zh) 2016-12-15 2018-12-19 預防動脈粥樣硬化及其併發症的藥物及其用途
HK18116702.5A HK1257583A1 (zh) 2016-12-15 2018-12-28 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途

Family Applications Before (5)

Application Number Title Priority Date Filing Date
HK18116276.1A HK1257240A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
HK18116273.4A HK1257237A1 (zh) 2016-12-15 2018-12-19 預防和治療脂肪肝的藥物及其用途
HK18116275.2A HK1257239A1 (zh) 2016-12-15 2018-12-19 預防和治療肥胖症的藥物及其用途
HK18116272.5A HK1257236A1 (zh) 2016-12-15 2018-12-19 預防和治療高脂血症的藥物及其用途
HK18116270.7A HK1257234A1 (zh) 2016-12-15 2018-12-19 治療冠狀動脈粥樣硬化及其併發症的藥物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18116702.5A HK1257583A1 (zh) 2016-12-15 2018-12-28 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途

Country Status (2)

Country Link
CN (8) CN108210895A (zh)
HK (7) HK1257240A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108671226A (zh) * 2018-08-08 2018-10-19 广州铭康生物工程有限公司 有效治疗中心静脉导管并发症的药物及其用途
CN110093412A (zh) * 2019-03-29 2019-08-06 南方医科大学南方医院 用于诊断动脉粥样硬化的分子标志物ugp2及应用
CN111100928A (zh) * 2020-01-09 2020-05-05 武汉科技大学 动脉粥样硬化生物标志物及动脉粥样硬化诊断试剂盒
CA3169325A1 (en) * 2020-02-26 2021-09-02 Jinan Li Method and drug for preventing and treating abnormal blood pressure condition
CN112305120B (zh) * 2020-10-30 2022-02-08 河北医科大学第二医院 代谢物在动脉粥样硬化性脑梗死中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408431A (zh) * 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 治疗与新生血管生成相关疾病的基因工程药物
MXPA04007585A (es) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
CN101518534A (zh) * 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
CN1726191A (zh) * 2002-12-10 2006-01-25 惠氏公司 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代的吲哚氧代－乙酰氨基乙酸衍生物
EP1666469A4 (en) * 2003-09-11 2008-12-03 Inst Med Molecular Design Inc INHIBITOR OF INHIBITOR-1 PLASMOGENIC ACTIVATOR
CA2563675C (en) * 2004-04-22 2012-08-28 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
WO2006095713A1 (ja) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
JPWO2007111242A1 (ja) * 2006-03-24 2009-08-13 ロート製薬株式会社 メタボリック症候群改善剤
CN101573134B (zh) * 2006-08-28 2013-03-06 李季男 抗感染候选药物
JP2010506957A (ja) * 2006-10-20 2010-03-04 ダウ グローバル テクノロジーズ インコーポレイティド メタボリックシンドロームを予防または処置するための水溶性セルロース誘導体の使用
AU2008314979A1 (en) * 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Inhibitor of PAI-1 production
US20090239868A1 (en) * 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
HUE029550T2 (en) * 2009-08-12 2017-03-28 Univ Cornell Methods of preventing or treating metabolic syndrome
US20120114652A1 (en) * 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
KR20140015289A (ko) * 2011-01-05 2014-02-06 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민 변이체
SG193258A1 (en) * 2011-03-03 2013-10-30 Tersus Pharmaceuticals Llc COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE
CN102188699A (zh) * 2011-05-06 2011-09-21 南京农业大学 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
RU2604810C2 (ru) * 2011-08-12 2016-12-10 Тромбодженикс Н.В. Варианты плазминогена и плазмина
CN102532326B (zh) * 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
ES2770507T3 (es) * 2013-08-13 2020-07-01 Sanofi Sa Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos
US20160199466A1 (en) * 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis

Also Published As

Publication number Publication date
CN108210904A (zh) 2018-06-29
CN108210902A (zh) 2018-06-29
HK1257239A1 (zh) 2019-10-18
HK1257236A1 (zh) 2019-10-18
HK1257583A1 (zh) 2019-10-25
CN108210895A (zh) 2018-06-29
CN108210896A (zh) 2018-06-29
CN108210906A (zh) 2018-06-29
CN108210898A (zh) 2018-06-29
HK1257237A1 (zh) 2019-10-18
CN108210900A (zh) 2018-06-29
HK1257234A1 (zh) 2019-10-18
HK1257240A1 (zh) 2019-10-18
CN108210914A (zh) 2018-06-29

Similar Documents

Publication Publication Date Title
IL279001A (en) Nasal medicines and methods of using them
IL263510A (en) Use of myostatin inhibitors and combined treatments
IL250415B (en) Antibodies against pd-l and methods of using them
ZA201605639B (en) Hppd variants and methods of use
GB201617508D0 (en) Use of Barocaloric materials and Barocaloric devices
EP3209213A4 (en) Surgical devices and methods of use thereof
FI3548033T3 (fi) Yhdisteitä ja menetelmiä niiden käyttämiseksi
EP3177199A4 (en) Medical devices and methods of placement
GB201418350D0 (en) Dispenser and methods of use thereof
EP3092479A4 (en) Surgical devices and methods of use thereof
ZA201606243B (en) Hppd variants and methods of use
HK1259022A1 (zh) 腸道餵養裝置和相關使用方法
HK1257233A1 (zh) 預防動脈粥樣硬化及其併發症的藥物及其用途
HK1258349A1 (zh) Hppd變體及使用方法
GB201609786D0 (en) Compounds and method of use
EP3265476A4 (en) Protoxin-ii variants and methods of use
ZA201607294B (en) Enamel products and methods of use
EP3177327A4 (en) Inhibitors of myh7b and uses thereof
EP3277304A4 (en) Protoxin-ii variants and methods of use
EP3349695A4 (en) CORPECTOMY DEVICE AND METHOD OF USE THEREOF
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201805977B (en) Mycobacteriophages capable of delivering auto-luminescent elements and uses thereof
GB201413530D0 (en) Treatment and prevention of malaria
EP3156054A4 (en) Medicine for preventing and/or treating stress-induced diseases
PT3503885T (pt) Composição farmacêutica e métodos de utilização